Axsome Therapeutics, Inc. (AXSM)
收市後：
| 前收市價 | 71.10 |
| 開市 | 71.53 |
| 買盤 | 73.00 x 100 |
| 賣出價 | 73.16 x 100 |
| 今日波幅 | 70.30 - 74.33 |
| 52 週波幅 | 55.02 - 98.40 |
| 成交量 | |
| 平均成交量 | 724,903 |
| 市值 | 3.462B |
| Beta 值 (5 年，每月) | 1.10 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.27 |
| 業績公佈日 | 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 123.00 |
Insider Monkey15 Most Black States in the US
In this article, we will be taking a look at the 15 most black states in the US. If you do not want to learn about the demographics of global black population, head straight to the 5 Most Black States in the US. Overview of the Global Black Population: Demographics, Trends, and Immigration Patterns The […]
ZacksAxsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
InvestorPlace3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy biotech stocks are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. Given the timeline of clinical trials and new rele
